|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ski, MD, PhD
Department of Thoracic Surgery of the Pulmonary Hospital, ul. G
adkie 1, Zakopane, 34-500 Poland
(Email: marcinz@mp.pl).
| The first 20% of the full text of this article appears below. |
To the Editor:
I read with interest the article Yu and colleagues [1]. The authors should be congratulated for the relatively large group of patients. The quantitative evaluation of the patients by the same neurologist with use of the new Myasthemia Gravis Foundation of America (MGFA) classification is another advantage of the study. However, I have several serious concerns about this study.
The most serious disadvantage is the absence of information regarding treatment of patients with oropharyngeal involvement and myasthenia before surgery. The authors
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |